Mounjaro cost in Alberta.

Direct answer

In Alberta, cash-pay Mounjaro KwikPens are priced off Lilly’s submitted list of about C$300 (2.5 / 5 mg), C$420 (7.5 / 10 mg), and C$540 (12.5 / 15 mg) per ~4-week pen, plus pharmacy markup and dispensing — illustrative counter quotes run roughly C$320–$650+. As of 5 October 2026, Mounjaro is not listed on the public ADBL. Zepbound is the separately authorized tirzepatide brand for weight management; coverage is private-plan or cash.

Illustrative retail cash prices (Calgary, Edmonton, Red Deer, Lethbridge)

Mounjaro in Canada is mostly dispensed as a multi-dose KwikPen (four weekly doses per pen). The anchor is the manufacturer’s submitted price published by Canada’s Drug Agency (CDA-AMC) in its 2026 Mounjaro review; what you pay at the counter adds pharmacy markup and a dispensing fee. Illustrative bands below blend that list price with 2026 reported pharmacy quotes (including one October 2026 Alberta Walmart report of about C$329 for a 2.5 mg pen). Confirm before you fill:

• Calgary / Edmonton big-box: warehouse and big-box pharmacies are often toward the lower end of a band when stocked; call with the DIN and ask for the all-in cash price.
• Full-service chains: Shoppers, Rexall, London Drugs, and grocery pharmacies can run higher once markup and dispensing are included.
• Red Deer / Lethbridge / smaller centres: similar bands, fewer quotes to compare — still worth calling two pharmacies.
• Quotes vary widely: some Canadian guides still cite higher bands (around C$405–$750 by dose). If your quote is far above list, ask the pharmacy what is included before you assume that’s the going rate.
• No generic tirzepatide: every tirzepatide product in Health Canada’s Drug Product Database is a Lilly brand (Mounjaro or Zepbound). Authorized generic semaglutide is a different molecule — molecule choice is a clinician decision; see semaglutide vs tirzepatide in Canada.

These are illustrative ranges, not guaranteed quotes. Never invent a co-pay from this page — your private plan’s special authorization, deductible, and co-insurance rules decide out-of-pocket when coverage applies.

Alberta Drug Benefit List reality (verify the live iDBL)

Alberta government-sponsored drug programs (for example Non-Group, Coverage for Seniors, and other Alberta Health programs) follow the Alberta Drug Benefit List, administered by Alberta Blue Cross. When we searched the Alberta Blue Cross interactive Drug Benefit List (iDBL) for “Mounjaro,” “tirzepatide,” and “Zepbound” on 5 October 2026, no tirzepatide product was listed — while Ozempic DINs appear under step therapy / special authorization (see our Ozempic cost in Alberta guide).

• The public DPP-4 / SGLT2 / GLP-1 special-authorization form (ABC 60012) names semaglutide (e.g. Ozempic) on the GLP-1 side — not tirzepatide.
• Alberta’s special-authorization policy only considers drugs and indications already covered under specified criteria, so an unlisted product generally can’t be approved through public special authorization.
• Canada’s Drug Agency issued a 2026 recommendation that public plans reimburse Mounjaro for adults with type 2 diabetes (with metformin-based combinations) only with conditions — including price reductions and use within existing public GLP-1 criteria. That is a national recommendation, not an Alberta listing. Price negotiation through the pan-Canadian Pharmaceutical Alliance and an Alberta decision would still need to happen, and may not.

Treat every “not covered” statement as time-stamped. The iDBL is updated close to real time and Alberta posts monthly ADBL updates — re-check before you budget.

Private Alberta Blue Cross / employer plans

For most working Albertans, tirzepatide coverage — if any — comes through an employer or individual plan (often Alberta Blue Cross–administered). Lilly Canada markets Mounjaro as covered by most private plans; that is a manufacturer claim, not a statement about your plan. We cannot invent your co-pay.

• Mounjaro (type 2 diabetes): many plans require prior / special authorization and may police the diagnosis. Ask HR or the insurer for the actual form and whether tirzepatide DINs are listed, carved out, or capped.
• Zepbound (weight management): Alberta Blue Cross publishes a weight-loss drug special-authorization form for employer plans (ABC 60130) that lists tirzepatide (Zepbound) alongside Wegovy, Saxenda, and Contrave. It asks for pre-treatment BMI and weight, weight-related comorbidities and previous failed weight-management interventions for BMI 27 to under 30, and allows a maximum of two trials per drug per lifetime. The form exists only for plans that include weight-management coverage — many employer plans exclude it entirely.
• A prescription does not equal plan approval, and a denied claim may need a documented resubmission with complete history.
• Lilly’s official Canadian savings programs (mymounjaro and myzepbound) may reduce out-of-pocket for some cash-pay or privately insured patients. Eligibility, exclusions, and stacking rules are program-specific — verify on the official sites.

For the semaglutide side of this conversation, see Wegovy in Alberta — Blue Cross notes.

Zepbound vs Mounjaro in Alberta (clearing up the confusion)

Search “Zepbound Alberta” and you’ll hit U.S. pages, U.S. prices, and forum posts saying Zepbound “isn’t in Canada.” Here’s what Health Canada’s own records show:

• Zepbound is authorized and marketed in Canada. Health Canada issued its Notice of Compliance in May 2025, and the Drug Product Database lists six Zepbound KwikPen strengths (2.5 mg to 15 mg) with status “Marketed” (first marketed July 2025).
• Same molecule, different authorization. Mounjaro is authorized to improve glycemic control in adults with type 2 diabetes. Zepbound is authorized for chronic weight management, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition (Zepbound product monograph). Using Mounjaro for weight management alone is off-label — a clinician decision, and a common reason private claims get questioned.
• Not to be combined. The Zepbound monograph says it should not be used together with other tirzepatide products (such as Mounjaro) or any GLP-1 receptor agonist.
• Similar list prices. Lilly’s submitted Canadian list prices for Zepbound KwikPens match Mounjaro’s tiers (about C$300 / C$420 / C$540 per pen by dose). Lilly Canada advertises starting Zepbound “as low as $300/month” with its savings card (exclusions apply; dispensing fees not included).
• Public coverage: not on the ADBL as of 5 October 2026. CDA-AMC’s 2026 Zepbound review recommended public reimbursement only for a narrow group — adults with a BMI of 27 or more and prediabetes plus at least one unsuccessful dietary attempt, with renewal tied to at least 5% weight loss. That is a recommendation, not Alberta coverage.
• U.S. programs don’t apply. U.S. self-pay offers, vials, and U.S.-dollar pricing are not available at Alberta pharmacies. Cross-border “Zepbound” sellers are a counterfeit risk, not a shortcut.

Three scenarios

Scenario A — Calgary resident, type 2 diabetes, no private drug benefits. Expect full cash-pay at illustrative retail (~C$320–$650+ per pen by dose) plus dispensing. Public ADBL help for Mounjaro is not listed today. Ask your clinician whether a Health Canada–authorized option that is on the ADBL (such as Ozempic under special authorization, when criteria fit) is clinically appropriate — that’s a medical decision, not a cost hack we can recommend from here. See Ozempic cost in Alberta.

Scenario B — Edmonton resident, employer plan through Alberta Blue Cross with weight-management coverage. If a clinician prescribes Zepbound, the plan may require the weight-loss special-authorization form (BMI, comorbidities, prior attempts). After approval, claims may adjudicate at plan rules rather than full retail; renewal paperwork and the two-trials-per-drug limit matter. Out-of-pocket remains plan-specific.

Scenario C — Lethbridge or Red Deer resident, weight management, no diabetes, asking for “Mounjaro.” Expect the conversation to land on Zepbound (the weight-management authorization) or another option your clinician chooses — and on private coverage or cash. Don’t expect the public ADBL to help today. Compare Alberta-serving clinics in our provider directory for visit and partner-pharmacy pricing — prescription not guaranteed, individual results vary.

Legit ways to save (not imports)

1. Pharmacy shop. Call Calgary, Edmonton, Red Deer, or Lethbridge pharmacies with the DIN and ask for today’s all-in cash price. Gaps of tens of dollars per pen are common.
2. Official manufacturer savings card. Check Lilly Canada’s mymounjaro / myzepbound programs. Avoid third-party “coupon” sites that push gray-market product.
3. Multi-pen fills. Once dose-stable, ask whether a multi-pen dispense is clinically appropriate — one dispensing fee instead of several.
4. Special-authorization diligence. If a private claim denies, ask which criteria were missing; incomplete BMI, comorbidity, or prior-therapy history is a frequent fixable failure.
5. Keep receipts. Prescription drugs are generally eligible medical expenses for the medical expense tax credit — confirm with your tax preparer.
6. Telehealth + partner pharmacy pricing. Some Alberta-serving clinics in our provider directory may quote below local retail through a partner pharmacy — compare, don’t assume.

What you should not do: buy “Mounjaro,” “Zepbound,” “tirzepatide,” or research-use vials from gray-market or overseas sellers, or compounded knock-offs. Counterfeit and contaminated products have been documented in international shipments, and there is no legitimate Canadian shortcut around authorized pharmacy channels. See research-use-only peptides — the Canadian truth.

FAQ

How much does Mounjaro cost in Calgary or Edmonton?

Lilly’s submitted Canadian list prices are about C$300 per 2.5 mg or 5 mg KwikPen, C$420 per 7.5 mg or 10 mg, and C$540 per 12.5 mg or 15 mg (one pen is about a 4-week supply). Pharmacies add markup and dispensing fees, so illustrative 2026 counter quotes often run roughly C$320–$370, C$450–$510, and C$580–$650+ respectively. Call Calgary or Edmonton pharmacies with the DIN — these are not personal quotes.

Does the Alberta Drug Benefit List or Alberta Health cover Mounjaro?

As of 5 October 2026, Mounjaro (tirzepatide) does not appear on the Alberta Drug Benefit List in the Alberta Blue Cross interactive search, and the public GLP-1 special-authorization form names semaglutide, not tirzepatide. Canada’s Drug Agency recommended conditional public reimbursement for type 2 diabetes in 2026, but national price negotiation and an Alberta listing decision would still need to follow. Re-check the live iDBL before you budget.

Is Zepbound available in Alberta, and is it different from Mounjaro?

Yes. Zepbound is Eli Lilly’s Health Canada–authorized tirzepatide brand for chronic weight management, and Health Canada’s Drug Product Database lists six Zepbound KwikPen strengths as marketed. Mounjaro is the same molecule authorized for type 2 diabetes. They have different DINs and indications, should not be used together, and private plans often treat them differently. Your clinician decides which, if either, is appropriate.

Does Alberta Blue Cross cover Zepbound or Mounjaro?

Public ADBL coverage is not listed for either as of this writing. Some Alberta Blue Cross employer plans that include weight-management drugs use a special-authorization form that names Zepbound and asks for BMI, comorbidities for BMI 27–29.9, and prior weight-management attempts, with a maximum of two trials per drug per lifetime. Whether your plan covers it at all depends on your employer’s plan design — ask the plan administrator.

Can Alberta telehealth prescribe Mounjaro or Zepbound?

Licensed clinicians serving Alberta — in person or via telehealth — may assess whether a Health Canada–authorized tirzepatide product is appropriate and help with private-plan paperwork. A prescription and coverage approval are never guaranteed, and individual results vary. Compare Alberta-serving clinics in our provider directory and treat outbound clinic links as possibly affiliate.

Sources (re-check before you act)

• Alberta Blue Cross iDBL — search “Mounjaro” / “tirzepatide” (no listing found 2026-10-05)
• Alberta Blue Cross — DPP-4 / SGLT2 / GLP-1 special-authorization form (ABC 60012)
• Alberta Blue Cross — weight-loss drugs special-authorization form for employer plans (ABC 60130)
• Alberta Blue Cross — 2026 drug pipeline for employer plans
• Health Canada Drug Product Database (search Mounjaro / Zepbound)
• Health Canada — Summary Basis of Decision, Mounjaro
• Zepbound Canadian product monograph (PDF)
• CDA-AMC reimbursement recommendation — tirzepatide (Mounjaro), 2026
• CDA-AMC reimbursement recommendation — tirzepatide (Zepbound), 2026
• pCPA — brand-name drug negotiations
• Lilly Canada — Mounjaro · Lilly Canada — Zepbound

Prairie twins: Mounjaro cost in Saskatchewan · Ozempic cost in Alberta · Wegovy Alberta / Blue Cross · Semaglutide vs tirzepatide.

Alberta GLP-1 access → Compare Alberta-serving providers

Informational eligibility quiz Felix details May be affiliate Maple details May be affiliate